Back to funds
View filing
NEA Management Company, LLC
hedge fundUpdated 27 days agoManaged by Nea Management Company, Llc • Latest filing Q2 2026
Portfolio value
$1.6B
Q2 2026
Filings
14
Quarterly 13F history
Top-10 concentration
100.0%
Weight of largest holdings
Annualized return
6.7%
Implied from 13F holdings
Portfolio value history
13F-disclosed portfolio value over 14 quarters
Show data table
| Period | Portfolio value |
|---|---|
| Q1 2023 | $1.4B |
| Q2 2023 | $1.3B |
| Q3 2023 | $1.3B |
| Q4 2023 | $1.5B |
| Q1 2024 | $1.6B |
| Q2 2024 | $1.3B |
| Q3 2024 | $1.8B |
| Q4 2024 | $1.8B |
| Q1 2025 | $1.3B |
| Q2 2025 | $1.3B |
| Q3 2025 | $1.8B |
| Q4 2025 | $2B |
| Q1 2026 | $1.8B |
| Q2 2026 | $1.6B |
Top holdings
26 positions as of Q2 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | T TRVI Trevi Therapeutics, Inc. | $246.6M | 13.22M | 15.53% | — |
| 2 | M MBX MBX Biosciences, Inc. | $199.5M | 3.61M | 12.56% | — |
| 3 | M MNST Monte Rosa Therapeutics, Inc. | $186.2M | 7.69M | 11.72% | — |
| 4 | C CELC Celcuity Inc. | $179M | 1.71M | 11.27% | — |
| 5 | S SGP Spyglass Pharma, Inc. | $164.6M | 7.39M | 10.36% | — |
| 6 | S SVRA Savara, Inc. | $150.7M | 24.47M | 9.49% | — |
| 7 | Z ZBIO Zenas BioPharma, Inc. | $102.1M | 4.02M | 6.43% | — |
| 8 | C COUR Coursera, Inc. | $72.6M | 12.87M | 4.57% | — |
| 9 | A AUPH Aurinia Pharmaceuticals, Inc. | $67.4M | 3.97M | 4.24% | — |
| 10 | C CRSP CRISPR Therapeutics AG | $57.7M | 1.06M | 3.64% | — |
| 11 | O ORIC ORIC Pharmaceuticals, Inc. | $44.6M | 4.12M | 2.81% | — |
| 12 | P PHAT Phathom Pharmaceuticals, Inc. | $21.3M | 1.96M | 1.34% | — |
| 13 | K KRRO Korro Bio, Inc. | $17.1M | 1.30M | 1.08% | — |
| 14 | X XFOR X4 Pharmaceuticals, Inc. | $15.1M | 3.23M | 0.95% | — |
| 15 | C CEVA Champions Oncology, Inc. | $10.6M | 1.71M | 0.66% | — |
| 16 | N NKTX Nkarta, Inc. | $10.1M | 3.57M | 0.64% | — |
| 17 | C CVRX CVRx, Inc. | $10M | 1.95M | 0.63% | — |
| 18 | B BDTX Black Diamond Therapeutics, Inc. | $8.2M | 4.45M | 0.52% | — |
| 19 | K KPTI Karyopharm Therapeutics Inc. | $5.6M | 576.8K | 0.35% | — |
| 20 | I IVEVF Inventiva SA | $5.5M | 1.46M | 0.35% | — |